Nemolizumab

Specification

• Cat#: THA-0128
• Product Name: Nemolizumab
• Description: Nemolizumab is an interleukin-31 receptor alpha antagonist used to treat prurigo nodularis in adults.
• Sequences: Nemolizumab heavy chain: QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYTLETWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKSCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSP Nemolizumab light chain: DIQMTQSPSSLSASVGDRVTITCQASEDIYSFVAWYQQKPGKAPKLLIYNAQTEAQGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYDSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
• Molecular Weight: 144000.0 Da (approximate)
• Introduction: Nemolizumab is a humanized monoclonal modified immunoglobulin 2 (IgG2) antibody directed against interleukin-31 receptor alpha (IL-31RA), which is an endogenous cytokine implicated in the pathophysiology of various skin inflammatory disorders. By binding to IL-31RA, nemolizumab blocks the IL-31 signalling cascades that lead to inflammation. Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis. It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: C6384H9814N1678O2034S48
• Appearance: Solid

Pharmaceutical Information

• Pharmacodynamics: Nemolizumab is a neuroimmune response modulator. In a phase III clinical trial with adults who have moderate-to-severe prurigo nodularis, treatment with nemolizumab resulted in an improvement in the signs and symptoms of prurigo nodularis, including an itch response and itch-related sleep disturbances.
• Targets: Interleukin-31 receptor subunit alpha